Please try another search
For the six months ended 30 June 2018, ImmunoCellular Therapeutics Ltd revenues was not reported. Net loss decreased 87% to $1.3M. Lower net loss reflects Research and development decrease of 98% to $350K (expense), Interest expense decrease from $883K (expense) to $0K, Recovery of legal fees increase from $0K to $422K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.81 to -$0.03.
Period Ending: | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -0.31 | -1.03 | -0.43 | -3.9 |
Net Income | -0.31 | -1.02 | -0.43 | -3.9 |
Period Ending: | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 |
---|---|---|---|---|
Total Assets | 3.83 | 5.16 | 7.01 | 6.78 |
Total Liabilities | 0.4 | 1.49 | 2.36 | 7.3 |
Total Equity | 3.43 | 3.67 | 4.65 | -0.52 |
Period Ending: | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -3.78 | -1.6 | -16.67 | -11.74 |
Cash From Investing Activities | 0 | 0 | ||
Cash From Financing Activities | 0 | 0 | 11.86 | 6.31 |
Net Change in Cash | -3.78 | -1.6 | -4.81 | -5.43 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review